Bank Julius Baer & Co. Ltd Zurich Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

Bank Julius Baer & Co. Ltd Zurich decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 54.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,245,041 shares of the biopharmaceutical company’s stock after selling 1,462,716 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Bristol Myers Squibb were worth $67,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares in the last quarter. EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $32,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at approximately $35,000. Finally, Garner Asset Management Corp purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on BMY shares. Cantor Fitzgerald increased their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Bank of America decreased their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. UBS Group restated a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.31.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb signed a global collaboration and licensing deal with Hengrui Pharma covering 13 early-stage drug programs, potentially bringing in up to $15.2 billion in milestone payments and strengthening its R&D pipeline. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: The partnership gives Bristol Myers Squibb broader access to promising oncology, hematology, and immunology assets, which could support long-term growth and help offset future revenue losses from older drugs. China’s Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
• Neutral Sentiment: Recent coverage also highlighted that Bristol Myers Squibb beat first-quarter earnings and revenue estimates, which supports the stock’s fundamental story but is less immediate than the Hengrui announcement. Bristol-Myers Squibb Company (BMY) Myers Beats Quarterly Profit Estimates
• Negative Sentiment: Some reports note that BMY shares had been falling in recent sessions, reflecting ongoing investor caution around patent-cliff risks and valuation concerns before the deal news. Bristol-Myers Squibb shares fell for seventh consecutive session

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY stock opened at $56.40 on Thursday. The stock’s fifty day moving average is $58.83 and its two-hundred day moving average is $55.25. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market capitalization of $115.17 billion, a P/E ratio of 15.84, a PEG ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the company earned $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.3 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.